Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Huntington's patients: drug eases involuntary movements

NCT ID NCT07601516

Symptom relief Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study looked at how well and how safely deutetrabenazine works for Chinese adults with Huntington's disease who have chorea (uncontrolled movements). Fifty patients took the drug as part of their normal care. The main goal was to see if chorea scores improved, especially in those taking at least 24 mg daily. The study also tracked side effects and serious events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

50 people

The number who actually took part.

Started

Feb 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with clinically confirmed diagnosis of chorea associated with Huntington's Disease (HD) * Participants whose baseline total maximal chorea (TMC) score ≥ 8 * Participants who are deutetrabenazine-naïve before study entry or who did not receive deutetrabenazine within 30 days of study entry, and who are about to be treated with deutetrabenazine for chorea associated with HD * Participants who have provided written consent for the use of personal and medical information for study purposes Exclusion Criteria: * Participants who have an unstable or serious medical or psychiatric illness at baseline * Participants with any history of suicidality, untreated or inadequately treated depression * Participants with certain comorbidities, including hepatic impairment, congenital long QT syndrome, and clinically significant cardiac arrhythmias. * Participants who received reserpine within 20 days of deutetrabenazine treatment initiation * Participants who received monoamine oxidase inhibitors within 14 days of deutetrabenazine treatment initiation * Participants who received vesicular monoamine transporter 2 (VMAT2) inhibitors, e.g., tetrabenazine or valbenazine, within 30 days of deutetrabenazine treatment initiation * Participants unable to provide a written consent for the study. * Participants who are participating in another study that includes treatment with an investigational drug and/or intervention at the same time as enrolment in the current study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOREA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

choreatic disease Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOREA Huntington's disease

Contacts and locations

Locations

  • Teva Investigational Site 01

    Chengdu, 610041, China

  • Teva Investigational Site 02

    Beijing, 100070, China

  • Teva Investigational Site 03

    Beijing, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.